The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–216 of 216
The Odyssey of MeCP2 and Parental Imprinting
LaSalle, J. M. (2007) · Epigenetics · doi:10.4161/epi.2.1.3697 · Cited by 53
Preparation of enzymatically active recombinant class III protein deacetylases
North, B. J., Schwer, B., Ahuja, N., Marshall, B. L., & Verdin, E. M. (2005) · Methods · doi:10.1016/j.ymeth.2005.03.004 · Cited by 52
Mai, A., Massa, S., Rotili, D., Pezzi, R., Bottoni, P., Scatena, R., Meraner, J., & Brosch, G. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.081 · Cited by 51
Challenges and opportunities in clinical trials for spinal muscular atrophy
Hirtz, D., Iannaccone, S. T., Heemskerk, J., Gwinn, K. A., Moxley, R., & Rowland, L. P. (2005) · Neurology · doi:10.1212/01.wnl.0000183282.10946.c7 · Cited by 50
Friedreich's Ataxia: Clinical Aspects and Pathogenesis
Pandolfo, M. (1999) · Seminars in Neurology · doi:10.1055/s-2008-1040847 · Cited by 49
Class IIA HDACs in the regulation of neurodegeneration
Majdzadeh, N., Morrison, B. E., & D’Mello, S. R. (2007) · Frontiers in bioscience · doi:10.2741/2745 · Cited by 44
Sun, J.-M. (2003) · Methods · doi:10.1016/s1046-2023(03)00083-5 · Cited by 44
Design and Synthesis of a Potent Histone Deacetylase Inhibitor
Liu, T., Kapustin, G. V., & Etzkorn, F. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061082q · Cited by 42
The Rubinstein–Taybi syndrome: modeling mental impairment in the mouse
Barco, Á. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00320.x · Cited by 37
Ellis, J. J., Valencia, T. G., Zeng, H., Roberts, L. D., Deaton, R. A., & Grant, S. R. (2003) · Springer eBooks · doi:10.1007/978-1-4757-4712-6_20 · Cited by 33
Drug targeting of dysregulated transcription in Huntington's disease
Kazantsev, A. G., & Hersch, S. M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.02.005 · Cited by 33
Self-citationTranscription meets metabolism in neurodegeneration
Ross, C. A., & Thompson, L. M. (2006) · Nature Medicine · doi:10.1038/nm1106-1239 · Cited by 31
Self-citationTranscription Regulation by Histone Deacetylases
Wang, S., Yan‐Neale, Y., Zeremski, M., & Cohen, D. (2004) · Novartis Foundation symposium · doi:10.1002/0470862637.ch18 · Cited by 26
Ellis, J. J., Valencia, T. G., Zeng, H., Roberts, L. D., Deaton, R. A., & Grant, S. R. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1021158216582 · Cited by 26
Chandler, S. P., Kansagra, P., & Hirst, M. C. (2003) · BMC Molecular Biology · doi:10.1186/1471-2199-4-3 · Cited by 16
Neuroimaging in Neuropsychiatry
Broderick, D. F. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.05.007 · Cited by 13
Research works printed but not linked: 5
- Gallen, C. C. Strategic challenges in neurotherapeutic pharmaceutical development. NeuroRx 1, 165–180 (2004). · doi:10.1602/neurorx.1.1.165
- Thomas, E. A. et al. The histone deacetylase inhibitor, HDACi 4b, ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA (in the press).
- Mai, A. et al. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. Med. Chem. 1, 245–254 (2005). · doi:10.2174/1573406053765431
- Khan, N. et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409, 581–589 (2008). · DOI · Paper page
- Galletti, P. et al. Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells. Nephrol. Dial. Transplant. 20, 1551–1558 (2005). · doi:10.1093/ndt/gfh846
Cited by
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Chemistry and Biology Of Multicomponent Reactions
Dömling, A., Wang, W., & Wang, K. (2012) · Chemical Reviews · doi:10.1021/cr100233r · Cited by 2,547
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes
Wang, Z., Zang, C., Cui, K., Schones, D. E., Barski, A., Peng, W., & Zhao, K. (2009) · Cell · doi:10.1016/j.cell.2009.06.049 · Cited by 1,344
“However, the drug development community faces significant challenges in the selection and design of drugs for clinical candidates, partially because of the lack of known targets of HATs and HDACs (Kazantsev and Thompson, 2008).”
BackgroundTargeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Metadata
- Authors
- Kazantsev, A. G., & Thompson, L. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-10
- Volume
- 7
- Issue
- 10
- Pages
- 854-868
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1996277745
- Cited by
- 711
- References
- 216
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.